EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Drug repurposing in status epilepticus

Matthew C Walker

Epilepsy & Behavior · 2024

DOI: 10.1016/j.yebeh.2024.110109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsy & Behavior, 2024. Verfasst von Matthew C Walker. Beteiligte Einrichtung: Department of Clinical and Experimental Epilepsy, University College London Queen Square Institute of Neurology, London WC1N 3BG, UK. Electronic addr…. Hauptthemen laut MEDLINE: Anticonvulsants, Drug Repositioning, Status Epilepticus. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, UCLH Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment of status epilepticus (SE) has changed little in the last 20 years, largely because of the high risks and costs of new drug development for SE. Moreover, SE poses specific challenges to drug development, such as patient diversity, logistical hurdles, and the need for acute treatment strategies that differ from chronic seizure prevention. This has reduced the appetite of industry to develop new drugs in this area. Drug repurposing is an attractive approach to address this unmet need. It offers significant advantages, including reduced development time, lower costs, and higher success rates, compared to novel drug development. Here I demonstrate how novel methods integrating biological knowledge and computational methods can be applied to drug repurposing in status epilepticus. Biological approaches focus on addressing mechanisms underlying drug resistance in SE (using for example ketamine, tacrolimus and safinamide) and longer-term consequences (using for example omaveloxolone, celecoxib and losartan). Additionally, artificial intelligence platforms, such as ChatGPT, can rapidly generate promising drug lists, while in silico methods can analyze gene expression changes to predict molecular targets. Combining AI and in silico approaches has identified several candidate drugs, including metformin, sirolimus and riluzole, for SE treatment. Despite the promise of repurposing, challenges remain, such as intellectual property issues and regulatory barriers. Nonetheless, drug repurposing presents a viable solution to the high costs and slow progress of traditional drug development for SE. This paper is based on a presentation made at the 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures, in April 2024.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsDrug RepositioningStatus EpilepticusAnimalsHumans

Stichwörter der Autor:innen

Artificial intelligenceDrug repurposingGenomicsNeuroinflammationReactive oxygen speciesStatus epilepticus

Substanzen

Anticonvulsants

Autor:innen und Institutionen

  • Department of Clinical and Experimental Epilepsy, University College London Queen Square Institute of Neurology, London WC1N 3BG, UK. Electronic address: m.walker@ucl.ac.uk.

Förderung

  • National Institute for Health and Care Research
  • UCLH Biomedical Research Centre

Zitieren

APA

Walker, M. C. (2024). Drug repurposing in status epilepticus. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2024.110109

Vancouver

Walker MC. Drug repurposing in status epilepticus. Epilepsy & Behavior. 2024. doi:10.1016/j.yebeh.2024.110109

BibTeX
@article{Walker2024,
  author = {Walker, Matthew C},
  title = {Drug repurposing in status epilepticus},
  journal = {Epilepsy & Behavior},
  year = {2024},
  doi = {10.1016/j.yebeh.2024.110109}
}
Kostenlos starten →